Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1NETWORK 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Genitourinary 7

Conditions

Prostatic Neoplasms 6258Carcinoma, Renal Cell 1910Urinary Bladder Neoplasms 1669Kidney Neoplasms 929Breast Neoplasms 792Neoplasms 786Carcinoma, Transitional Cell 590Carcinoma, Non-Small-Cell Lung 522Neoplasm Metastasis 510Melanoma 484Ovarian Neoplasms 466Colorectal Neoplasms 451Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 289Stomach Neoplasms 273Sarcoma 265Uterine Cervical Neoplasms 262Non-Muscle Invasive Bladder Neoplasms 262Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 202Squamous Cell Carcinoma of Head and Neck 200Wilms Tumor 196Carcinoma, Hepatocellular 195Endometrial Neoplasms 188Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 144

Interventions

Docetaxel 3Androgen Antagonists 3enzalutamide 2darolutamide 2apalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Metastatic Hormone-sensitive Prostate Cancer × Genitourinary × Clear all
NCT05901649 2026-05-08

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06991556 2026-05-01

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT07031258 2025-06-22

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Nanfang Hospital, Southern Medical University

Not yet recruiting
50 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Bayer

Completed
106 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡